AN2 THERAPEUTICS, INC.

Analyst Reco. AN2 Therapeutics, Inc.

Equities

ANTX

US0373261058

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
2.42 ^USD	-2.02%		-5.47%	-88.19%

04-03	North American Morning Briefing : Powell Awaited -2-	DJ
04-02	JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform	04-02	MT
Leerink Partners Downgrades AN2 Therapeutics to Market Perform From Outperform, Adjusts PT to $7 From $23	02-13	MT
Oppenheimer Downgrades AN2 Therapeutics to Market Perform From Outperform	02-12	MT
Evercore ISI Downgrades AN2 Therapeutics to In Line from Outperform, Adjusts PT to $7 From $25	02-12	MT
JMP Securities Downgrades AN2 Therapeutics to Market Perform From Market Outperform	02-12	MT
JMP Securities Initiates AN2 Therapeutics With Market Outperform Rating, Price Target is $30	01-04	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $27 From $24, Maintains Outperform Rating	14/09/23	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $24 From $20, Maintains Outperform Rating	30/03/23	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $20 From $22, Maintains Outperform Rating	10/11/22	MT
Evercore ISI Initiates Coverage on AN2 Therapeutics With Outperform Rating, $25 Price Target	19/04/22	MT
Oppenheimer Initiates Coverage on AN2 Therapeutics With Outperform Rating, $22 Price Target	19/04/22	MT
Cowen Starts AN2 Therapeutics at Outperform	19/04/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer